ARQT FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades. https://ih.advfn.com/stock-market/NASDAQ/arcutis-biotherapeutics-ARQT/stock-news/92826417/fda-approves-arcutis-zoryve-roflumilast-topical